PDE5 inhibitors: considerations for preference and longâ•’term adherence
نویسندگان
چکیده
410. 4 Albersen M, Shindel AW, Mwamukonda KB, Lue TF. The future is today: emerging drugs for the treatment of erectile dysfunction. Expert Opinion Emerg Drugs 2010; 15: 467–80. 5 Albersen M, Shindel AW, Lue TF. Sexual dysfunction in the older man. Reviews in Clinical Gerontology 2009; 19(4): 237–248. 6 Montorsi F, Salonia A, Zanoni M et al. Current status of local penile therapy. Int J Impot Res 2002; 14 (Suppl. 1): S70–81. 7 McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med 2004; 1: 292–300. 8 McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2005; 2: 415–25; discussion 25–7. 9 Porst H, Giuliano F, Glina S et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 2006; 50: 351–9. 10 Porst H, Rajfer J, Casabé A et al. Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med 2008; 5: 2160–9. 11 Kang DH, Lee JY, Park SY et al. Efficacy and safety of tadalafil 5 mg administered once daily in Korean men with erectile dysfunction: a prospective, multicenter study. Korean J Urol 2010; 51: 647–52. 12 Hackett GI. Patient preferences in treatment of erectile dysfunction: the continuing importance of patient education. Clin Cornerstone 2005; 7: 57–65. 13 Mulhall J, King R, Glina S, Hvidsten K. Importance of and satisfaction with sex among men and women worldwide: results of the global better sex survey. J Sex Med 2008; 5: 788–95. 14 Eardley I, Dean J, Barnes T et al. The sexual habits of British men and women over 40 years old. BJU Int 2004; 93: 563–7. 15 Conaglen HM, Conaglen JV. Couples’ reasons for adherence to, or discontinuation of, PDE type 5 inhibitors for men with erectile dysfunction at 12 to 24-month follow-up after a 6-month free trial. J Sex Med 2012; 9: 857–65. 16 Sadovsky R, Brock GB, Gray M et al. Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: opening windows to enhanced sexual function and overall health. J Am Acad Nurse Pract 2011; 23: 320–30. 17 Goldstein I, Kim E, Steers WD et al. Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US. J Sex Med 2007; 4: 166–75. 18 McMahon CG. Treatment of erectile dysfunction with chronic dosing of tadalafil. Eur Urol 2006; 50:
منابع مشابه
Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil
Erectile dysfunction (ED) is a problem that may affect up to 52% of men between the ages of 40 and 70. It can be distressing because of its negative effect on self-esteem, quality of life, and interpersonal relationships. Oral phosphodiesterase-5 inhibitors (PDE5 inhibitors) are now the first choice of treatment in ED. The availability of three (sildenafil citrate, tadalafil, and vardenafil) we...
متن کاملPDE5 inhibitors: considerations for preference and long-term adherence.
INTRODUCTION Erectile dysfunction (ED) is a highly prevalent condition affecting nearly one in five men worldwide. The advent of phosphodiesterase type 5 inhibitors (PDE5i) has revolutionised the ED treatment landscape and provided effective, minimally invasive therapies to restore male sexual function. MATERIALS AND METHODS A pubmed search was performed of all English language articles from ...
متن کاملAdherence to Phosphodiesterase Type 5 Inhibitors in the Treatment of Erectile Dysfunction in Long-Term Users: How Do Men Use the Inhibitors?
INTRODUCTION The high effectiveness of phosphodiesterase type 5 inhibitors (PDE5-i) in the treatment of erectile dysfunction (ED) has been demonstrated. However, previous research shows that PDE5-i treatments have high discontinuation rates. AIM The main goals of this study were to (i) characterize the way men use PDE5-i and (ii) analyze the adherence to treatment, identifying the factors tha...
متن کاملTadalafil once daily in the management of erectile dysfunction: patient and partner perspectives
Erectile dysfunction (ED) is a prevalent condition that affects men and their partners. Significant improvements in the sexual lives of these couples have been achieved with the introduction of phosphodiesterase 5 (PDE5) inhibitors. A PDE5 inhibitor is now widely recognized as the first-line therapy for the majority of men with ED. Currently, three PDE5 inhibitors - sildenafil, tadalafil and va...
متن کاملTreatment effects of phosphodiesterase-5 inhibitors may improve with time following nerve-sparing radical prostatectomy.
OBJECTIVE Erectile dysfunction (ED) is common following radical prostatectomies, and phosphodiesterase type 5 inhibitors (PDE5 inhibitors) are generally considered the first choice of treatment. The purpose of this study was to analyze the long-term efficacy of PDE5 inhibitors in a group of men who did not achieve sufficient erectile function from the medication in the short term following surg...
متن کامل